Choose Your Language:Chinese (Simplified) Chinese (Traditional) Danish Dutch English French German Italian Polish Portuguese Spanish
Alexis (Lexy) Ahmad is an HCP Marketer for TYSABRI® at Biogen’s US Commercial Organization. She is a member of the 3rd cohort of Biogen’s IMPACT Leadership Development Program, a rotational program for MBA graduates. Prior to her current role, Lexy was the Director of Clinical Trials for the Georgetown University Multiple Sclerosis and Neuroimmunology Center, where she managed over 60 industry industry-sponsored clinical trials in MS, NMO, ALS, Parkinson Disease, Stroke, Epilepsy, and Migraine/Headache. As a core team member, Lexy helped lead the GU MS Center’s transformation to become the first Neurology Patient-Centered Specialty Home certified by the National Center for Quality Assurance. She is very passionate about understanding the challenges and successes of patient-centered care from a multi-stakeholder perspective. In addition to clinical trials at GU, Lexy enjoyed completing independent research projects exploring the functional impact and utility of Patient Reported Outcomes in MS and Huntington Disease studies.
Prior earned both her MBA (’21) and Bachelor’s degree in Psychology (COL ’13) from Georgetown University. She and her husband relocated to Somerville from Washington, D.C. in July 2021 with their golden retriever, Bruno, and are happy to now call the Boston area “home”!
Languages spoken: French
With a true passion for patients, and dedication to connecting patients/caregivers in need of resources and support, Stephanie Hamzo has built her career in rare and ultra-rare disease communities. Throughout many roles she held at AmerisourceBergen Canada, Vertex Pharmaceuticals, Alexion and now at Janssen, patient centricity and incorporating the patient voice & insights throughout the drug development and commercialization processes have been the center of her responsibilities. Stephanie’s early career in pharmacy assistance and direct patient care as a nurse led her to bring her passion for the patient forward to the pharmaceutical sector.
She brings a multi-disciplined experience to our strategic stakeholder planning, as well as gained experience in newborn screening, global and international public policy/health technology assessment.
Languages spoken: Bengali
Nabila Hoque is a Senior Clinical Research Manager at IVERIC bio, a biopharmaceutical company specializing in retinal diseases. She currently oversees a global Phase 3 Clinical Trial of over 400 patients with Dry Age-Related Macular Degeneration (AMD), and has a deep understanding of clinical trial operations at various stages of growth.
Nabila started her career in clinical research at Mount Sinai Medical School coordinating studies at the site-level, and later pivoted to clinical trial management on the sponsor side. She has contributed to running studies from start up to study closure while ensuring efficiency and compliance along the way. She also has a background in Cell Biology & Neuroscience with a Masters in Biomedical Sciences from Robert Wood Johnson Medical School. Nabila lives in Brooklyn and enjoys eating her way through NYC in her free time, and looks forward to contributing to the continued growth and success of TSF.
Chelsey earned her immunology PhD at Case Western Reserve University in Cleveland, Ohio, in 2016, and further studied immune mechanisms at the Ragon Institute of MGH, MIT and Harvard. When her brother Connor became temporarily blinded and paralyzed by NMOSD in 2014, Chelsey and her mom, Pam Judge, co-founded the Judge family-based non-profit in her brother’s name, aiming to raise awareness and research funds for NMOSD. She joined Sanofi MS/Neurology in 2017, where she is currently a Field Medical Scientific Associate Director, separate from her advocacy work.
Chelsey is an advocate for biomedical research funding and clear scientific communication and education. The non-profit funding has contributed to multiple research projects, including nerve repair. The Judge family has launched the annual Cleveland Clinic Mellen Center NMO Patient Day, as well as statewide Rare Disease Day with the National Organization for Rare Disorders.These initiatives bring together patients, advocates, clinicians, researchers and policy makers in the shared mission to improve the lives of rare disease patients and families. Chelsey created and hosted the ‘Demystifying NMO’ podcast, a TSF collaboration. Her hope is for patients to be empowered with education to make informed shared decisions with their clinical care team.
Kate has over a decade of life sciences consulting experience. As an Associate Principal with ZS, Kate advises her pharmaceutical clients on a broad range of business issues including marketing strategy and competitive readiness, launch planning, go-to-market strategy, org design, and field effectiveness. She serves clients in commercial, medical, and patient services functions, and has especially deep expertise in rare disease drug commercialization.
Kate is known for combining empathy and thoroughness with a fact-based approach to strategic problem solving. She is passionate about helping her clients effectively tackle challenges related to the evolving healthcare landscape to improve patient outcomes, especially in underserved patient populations and disease areas.
|cookielawinfo-checkbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".|
|cookielawinfo-checkbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".|
|cookielawinfo-checkbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".|